Chen He, Yang Heng, Cheng Qiu-Xiang, Ge Yong-Peng, Peng Qing-Lin, Zhang Ya-Mei, Cheng Gen-Hong, Wang Guo-Chun, Lu Xin
Department of Rheumatology China-Japan Friendship Hospital Beijing 100029 China.
Center for Systems Medicine Institute of Basic Medical Sciences Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100005 China.
Clin Transl Immunology. 2020 Oct 15;9(10):e1195. doi: 10.1002/cti2.1195. eCollection 2020.
To investigate the prevalence and clinical significance of anti-calreticulin autoantibodies (anti-CRT Ab) in a large cohort of idiopathic inflammatory myopathy (IIM) patients.
Sera from 469 patients with IIM, 196 patients with other connective tissue diseases, 28 patients with solid tumors and 81 healthy controls were screened for anti-CRT Ab by enzyme-linked immunosorbent assay using human recombinant CRT protein. Sera from 35 IIM patients were tested using an immunoprecipitation assay to confirm the presence of anti-CRT Ab. Subsequently, IIM-cancer patients were identified and divided into new-onset, remission and recurrent groups based on their cancer status. The relationships between anti-CRT Ab levels and IIM disease activity were also investigated.
Serum anti-CRT Ab was detected positive in 81 of the 469 (17.3%) IIM patients. Immunoprecipitated bands were observed at a molecular weight of 60 kDa corresponding to the CRT protein. The IIM patients with anti-CRT Ab more frequently had cancers compared to the patients without anti-CRT Ab. Moreover, the prevalence of anti-CRT Ab differed according to the cancer status. The IIM patients with recurrent cancers had a much higher prevalence of anti-CRT Ab than those with cancers in remission. Also, serum anti-CRT Ab levels positively correlated with disease activity at baseline and at follow-up visits.
We report the existence of serum anti-CRT Ab in IIM patients and demonstrate the possible association of anti-CRT Ab with malignancy in IIM patients. Serum anti-CRT Ab could serve as a novel candidate marker of cancer in IIM patients.
在一大群特发性炎性肌病（IIM）患者中调查抗钙网蛋白自身抗体（抗CRT抗体）的患病率及其临床意义。
采用人重组CRT蛋白，通过酶联免疫吸附试验对469例IIM患者、196例其他结缔组织病患者、28例实体瘤患者和81名健康对照者的血清进行抗CRT抗体筛查。对35例IIM患者的血清进行免疫沉淀试验，以确认抗CRT抗体的存在。随后，识别出IIM合并癌症患者，并根据其癌症状态分为新发、缓解和复发组。还研究了抗CRT抗体水平与IIM疾病活动度之间的关系。
469例IIM患者中有81例（17.3%）血清抗CRT抗体检测呈阳性。在对应于CRT蛋白的60 kDa分子量处观察到免疫沉淀条带。与无抗CRT抗体的患者相比，有抗CRT抗体的IIM患者患癌症的频率更高。此外，抗CRT抗体的患病率因癌症状态而异。复发癌症的IIM患者抗CRT抗体的患病率远高于缓解期癌症患者。而且，血清抗CRT抗体水平与基线和随访时的疾病活动度呈正相关。
我们报告了IIM患者血清中存在抗CRT抗体，并证明了抗CRT抗体与IIM患者恶性肿瘤之间可能存在关联。血清抗CRT抗体可作为IIM患者癌症的一种新型候选标志物。
